x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Society of Hematologic Oncology Insider news

Seriously simple podcasting

SOHO Insider delivers on the latest news in hematologic oncology and updates from the Society of Hematologic Oncology

science life sciences

All Episodes

00:13:45

Dr. Gloria Iacoboni on improving CAR T-cell therapy...

Society of Hematologic Oncology Insider news ·

2026/03/17

Gloria Iacoboni, MD, PhD, a hematologist at Vall d’Hebron University Hospital in Barcelona, Spain, spoke with Dr. James Day, a clinical research training fellow at UCL in London, during this SOHO Insider podcast episode recorded at the inaugural SOHO UK 2026 meeting. Dr. Iacoboni discussed strategies to improve outcomes in high-grade lymphoma, focusing on improved patient selection, the emergence of dual-targeted CAR T-cell products (CD19/CD20), and how circadian rhythms might impact infusion

en-US

00:06:12

Why clinicians should lead hospitals, according to...

Society of Hematologic Oncology Insider news ·

2026/03/10

Prof. Amanda Goodall, director of the Executive Master’s in Medical Leadership (EMML), a specialized MSc degree from Bayes Business School offering advanced leadership training to medical doctors, joined SOHO Insider podcast host Prof. Christopher Fox, a professor of hematology at Nottingham University Hospitals NHS Trust, for a discussion on expert leadership in healthcare.According to Prof. Goodall, expert leadership is the idea that organizations perform best when leaders are experts in

en-US

00:12:13

Prof. Cwynarski previews CNS, peripheral T-cell...

Society of Hematologic Oncology Insider news ·

2026/02/27

Prof. Kate Cwynarski, MD, PhD, joined SOHO Insider podcast host Megan Melody, MD, for a discussion previewing lymphoma sessions she will lead at the inaugural SOHO UK meeting, scheduled for March 3–4, 2026, in London.Prof. Cwynarski will chair a “Meet the Expert” roundtable on challenges and controversies in managing central nervous system (CNS) lymphoma. The session will include a seven-year update of the MARIETTA study, which examined treatment strategies for secondary CNS lymphoma, as well as

en-US

00:26:33

Dr. Tara Graff presents ‘Implementing bispecific...

Society of Hematologic Oncology Insider news ·

2026/02/16

The second session of the Community Oncology Brown Bag Series, hosted by SOHO Insider, held on February 11, 2026, and featured guest speaker Tara Graff, DO, MS, at Mission Cancer + Blood and director of their clinical research program. Dr. Graff discussed “Moving CAR T-cell therapies into the community setting.”This program is led by Loretta Nastoupil, MD, the SOHO Insider community oncology section editor. To register for the series, go to https://soho.click/community-oncology-series

en-US

00:03:31

Dr. DiPersio: Cross-sector partnerships needed to...

Society of Hematologic Oncology Insider news ·

2026/02/09

John DiPersio, MD, PhD, current president of SOHO and director of the Center for Gene and Cellular Immunotherapy at Washington University School of Medicine in St. Louis, Missouri, discusses the need for public-private partnerships to move novel therapies forward in the treatment of blood cancers. He also speaks about how cross-sector collaboration can create better research paths for the future.For SOHO 2026, Dr. DiPersio chose the theme “Advancing care through collaborative science,” a timely

en-US

00:17:04

Advances in essential thrombocythemia with Drs....

Society of Hematologic Oncology Insider news ·

2026/01/16

In this episode of the SOHO Insider podcast, Andrew Kuykendall, MD, assistant member at Moffitt Cancer Center, and Douglas Tremblay, MD, assistant professor of medicine at Icahn School of Medicine at Mount Sinai, discuss how to approach the treatment of essential thrombocythemia.“The first thing I do whenever a patient walks into the clinic with ET is think about their risk status,” Dr. Tremblay said. “When we speak about risk status, what we’re really speaking about is risk

en-US

00:09:48

Dr. Thomas Martin interviews 1st US patient treated...

Society of Hematologic Oncology Insider news ·

2026/01/10

In this episode of the SOHO Insider podcast, Thomas Martin, MD, professor of medicine at University of California, San Francisco, talks with patient Craig Chase, an American father of two who was diagnosed with myeloma in 2014; Chase was the only American to travel to Nanjing, China, in 2017 to receive ciltacabtagene autoleucel (cilta-cel; then LCAR-B38M). Chase shares his experience traveling to China for the therapy as a heavily-treated patient with limited treatment options. Chase talked about

en-US

24:22

Tara Graff, MD, talks community care and the CAR-T vs...

Society of Hematologic Oncology Insider news ·

2025/11/27

SOHO Insider lymphoma podcast host Megan Melody, MD, assistant professor at the University of South Florida, interviews Tara Graff, MD, director of clinical trials and lymphoma specialist at Mission Cancer and Blood, part of University of Iowa Health Care, on treating patients with blood cancers in community settings, and whether the future belongs to bispecific antibodies or CAR-T therapies.“To be able to give your patients these novel therapies is amazing,” Dr. Graff said on the podcast. “I think

en-US

1:34

A 2025 lymphoma snapshot from Julie Vose, MD, MBA

Society of Hematologic Oncology Insider news ·

2025/11/20

Ahead of SOHO Breakthroughs in Blood Cancers—and in the spirit of end-of-year lists—SOHO Insider asked Dr. Vose for her take on the biggest lymphoma developments of 2025. Her answer: bispecific antibodies continue to dominate the field.She noted that the biggest shift in the field is moving away from chemotherapy alone and toward immunotherapy and bispecific-based approaches. Dr. Vose will be speaking at 12:30 pm Central time on November 20, 2025, during SBBC. At 12:55 pm Central time, attendees

en-US

10:06

Does the future of myeloma treatment belong to...

Society of Hematologic Oncology Insider news ·

2025/11/19

In this SOHO Insider podcast, Saad Usmani, MD, chief of the myeloma service at Memorial Sloan Kettering Cancer Center, and Niels W C J van de Donk, MD, professor of hematology at Amsterdam UMC, provide an overview of immunotherapies. They discuss bispecific and trispecific antibodies, including early data from the trispecifics and the therapies moving into the frontline setting in multiple myeloma treatment. The pair spoke about the novel trispecific antibody JNJ-5322 that targets BCMA and GPRC5D

en-US

12:19

Drs. O’Brien, Jain discuss FLAIR trial, BTK degraders...

Society of Hematologic Oncology Insider news ·

2025/10/30

In this episode of the SOHO Insider podcast, Susan O’Brien, MD, a professor of medicine from the Chao Family Comprehensive Cancer Center at the University of California, Irvine Medical Center, and Nitin Jain, MD, professor of medicine in the Department of Leukemia at the University of Texas MD Anderson Cancer Center, discuss updated results from the phase 3 FLAIR trial; the pair also speak about Bruton’s tyrosine kinase degraders in treating CLL.

en-US

1:40

Sagar Lonial, MD, on what to expect at SOHO...

Society of Hematologic Oncology Insider news ·

2025/10/17

Sagar Lonial, MD, and Saad Usmani, MD, provide a sneak peek on what attendees can expect to learn at SOHO Breakthroughs in Blood Cancers (SBBC). Dr. Lonial will be the presenter of the myeloma session at the meeting. His talk is scheduled for 1:35 pm Central time on November 20, 2025.SBBC is a new virtual meeting from SOHO and is chaired by Hagop Kantarjian, MD, of the University of Texas MD Anderson Cancer Center. SBBC takes place at 8 am—5 pm Central time on November 20, 2025. Register today at

en-US

8:56

Dr. Eytan Stein joins Dr. Saad Usmani on SOHO Insider...

Society of Hematologic Oncology Insider news ·

2025/10/10

Saad Usmani, MD, chief of the myeloma service and Eytan Stein, MD, chief of the leukemia service, both from Memorial Sloan Kettering Cancer Center, discuss menin inhibitors and the future of leukemia research in this podcast episode of SOHO Insider. Dr. Stein discusses the development of the first menin inhibitor approved the US Food and Drug Administration for relapsed or refractory acute leukemia with a KMTA translocation. “The response rate is in the range of 60% to 70%,” noted Dr. Stein,

en-US

8:09

Drs. Melody, Phillips talk glofitamab in MCL

Society of Hematologic Oncology Insider news ·

2025/09/23

In this podcast episode recorded at the Thirteenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2025), Megan Melody, MD, from Tampa General Hospital, spoke with Tycel J. Phillips, MD, from the City of Hope Cancer Center, on the latest advancements in mantle cell lymphoma (MCL), including the phase 1/2 trial in relapsed or refractory MCL recently published in the Journal of Clinical Oncology.In the trial led by Dr. Phillips, the investigators evaluated glofitamab monotherapy in

en-US

16:10

Drs. Kuykendall and Gerds discuss myelofibrosis...

Society of Hematologic Oncology Insider news ·

2025/08/27

SOHO Insider myeloproliferative neoplasms podcast host Andrew Kuykendall, MD, associate member in the Department of Malignant Hematology at the Moffitt Cancer Center, and guest Aaron Gerds, MD, MS, an associate professor at the Cleveland Clinic, discuss anemia in myelofibrosis in a SOHO Insider podcast.“I put anemia near the top of the list, or at least an equal footing with spleen and symptoms,” Dr. Gerds said. He also noted that 40% of myelofibrosis patients face anemia at diagnosis, with

en-US

10:55

SOHO Insider leukemia podcast with Drs. O’Brien and...

Society of Hematologic Oncology Insider news ·

2025/08/19

Listen to Susan O’Brien, MD, professor of medicine, and Catherine C. Coombs, MD, associate professor of medicine, both of the Chao Family Comprehensive Cancer Center at the University of California, Irvine, on the SOHO Insider podcast.They discuss frontline chronic lymphocytic leukemia (CLL) treatments from the EHA 2025 meeting in Milan along with the AMPLIIFY trial, presented at the American Society of Hematology (ASH) Annual Meeting and Exposition in December 2024. The GAIA/CLL13 trial showed

en-US

13:36

Dr. Melody interviews Dr. Prica on Burkitt’s lymphoma...

Society of Hematologic Oncology Insider news ·

2025/08/06

SOHO Insider lymphoma podcast host Megan Melody, MD, an assistant professor at the University of South Florida and lymphoma and chimeric antigen receptor T-cell therapy specialist at Tampa General Hospital Cancer Institute interviews Anca Prica, MD, of Princess Margaret Cancer Centre, in this podcast episode.The pair discuss Dr. Prica’s paper on glofitamab and polatuzumab for refractory Burkitt’s lymphoma, which was published in The New England Journal of Medicine earlier in 2025.

en-US

8:47

SOHO President Phillip Scheinberg talks with Saad...

Society of Hematologic Oncology Insider news ·

2025/07/23

Saad Usmani, MD, chief of the myeloma service at Memorial Sloan Kettering Cancer Center, and Phillip Scheinberg, MD, president of the Society of Hematologic Oncology (SOHO), chat about SOHO’s vision, Annual Meeting, satellite meetings, and membership.To register for SOHO 2025, visit soho.click/2025. Become a SOHO member for free today. Listen to other SOHO Insider podcasts.

en-US

9:08

The journey of belantamab mafodotin in multiple myeloma

Society of Hematologic Oncology Insider news ·

2025/07/07

Host Saad Usmani, MD, chief of the myeloma service at Memorial Sloan Kettering Cancer Center in New York City, and Sagar Lonial, MD, FACP, professor and chair of the Department of Hematology and Medical Oncology at Winship Cancer Institute at Emory University, explore the journey of the antibody-drug conjugate (ADC) belantamab mafodotin, the first B-cell maturation antigen (BCMA)-targeted ADC approved by the US Food and Drug Administration (FDA) for patients with relapsed or refractory myeloma.Dr

en-US

12:07

Inside AML challenges with Drs. Jabbour, Daver

Society of Hematologic Oncology Insider news ·

2025/06/26

Elias Jabbour, MD, and Naval Daver, MD, both of the University of Texas MD Anderson Cancer Center, discuss challenges in TP53-mutated acute myeloid leukemia (AML) in this SOHO Insider podcast episode. Despite advances in other molecular subsets, TP53 AML has seen little meaningful progress in more than two decades. It remains a particularly aggressive form, especially common in older adults and therapy-related cases. Not all TP53 mutations are the same; prognosis worsens with high allelic burden,

en-US

24 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter